Literature DB >> 11308131

Ecstasy ingestion and fulminant hepatic failure: liver transplantation to be considered as a last therapeutic option.

J Garbino1, J A Henry, G Mentha, J A Romand.   

Abstract

Severe adverse effects due to 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) are reported with increasing frequency in the medical literature. The signs of acute toxicity most often seen are fulminant hyperthermia, hyperexcitatory states, acute renal failure and hyponatraemia. In 1992, hepatotoxicity was also described with unexplained jaundice and hepatomegaly after ingestion of MDMA. We report a case of severe toxic hepatitis following ingestion of MDMA with fulminant hepatic failure which required auxiliary liver transplantation. The diagnosis was necrotic toxic hepatitis following ecstasy ingestion. The outcome was successful, and the patient was discharged from ICU 20 d after surgery. Hepatotoxic effects of MDMA seem infrequent, but may be lethal; liver transplantation is the ultimate therapeutic option in some cases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11308131

Source DB:  PubMed          Journal:  Vet Hum Toxicol        ISSN: 0145-6296


  3 in total

1.  Drug interaction between ethanol and 3,4-methylenedioxymethamphetamine ("ecstasy").

Authors:  Vijay V Upreti; Natalie D Eddington; Kwan-Hoon Moon; Byoung-Joon Song; Insong J Lee
Journal:  Toxicol Lett       Date:  2009-04-05       Impact factor: 4.372

Review 2.  Drug-induced liver injury: is it somehow foreseeable?

Authors:  Giovanni Tarantino; Matteo Nicola Dario Di Minno; Domenico Capone
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

Review 3.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.